This page provides the material available for the Advisory Council meetings held in 2023.
October 30, 2023 — Advisory Council Meeting
During the meeting, the Advisory Council welcomed a new cohort of members and heard updates from federal agencies on key activities over the last quarter. A panel presented information on interventions to reduce the risk of developing dementia.
General Material:
Presentation Slides:
- Blood Pressure Lowering: A Practical Approach to the Public Health Goal of Reducing Risk for Cognitive Disability
- Effects of Hearing Intervention on Cognitive Decline: Results of the ACHIEVE Randomized Trial
- Risk Reduction Through Non-Pharmacological Intervention
- LatAm FINGERS Multivariate Intervention in Latin America
- Dementia Risk Reduction: A Public Health Approach
- NAPA Implementation Overview and Agency Progress
Videos:
July 31, 2023 — Advisory Council Meeting
During the meeting, the Advisory Council subcommittees presented their recommendations for adoption by the full Advisory Council. The meeting also included a presentation on the Alzheimer’s disease bypass budget from the National Institutes of Health (NIH), a National Healthy Brain Initiative Road Map Series update by the Centers for Disease Control and Prevention (CDC), and federal updates.
General Material:
Handouts:
- Draft 2023 Recommendations
- Guiding an Improved Dementia Experience (GUIDE) Model Fact Sheet
- Guiding an Improved Dementia Experience (GUIDE) Model Webpage
Presentation Slides:
- Federal Agency Updates
- Alzheimer’s Disease Bypass Budget
- Charting the Course to Better Brain Health
- 2023 Proposed Recommendations
Videos:
- "Welcome" through "Federal Updates"
- "Alzheimer’s Disease Bypass Budget" through "Updates from AAIC"
- "Subcommittee Recommendations"
- "Recommendation Voting" through "Adjourn"
May 8, 2023 — Advisory Council Meeting
During the meeting, the Advisory Council will hear presentations about the drug approval and coverage decision processes. A panel will also present on progress and challenges in translating research into clinical impact. Federal agencies will provide updates on activities during the last quarter.
General Material:
- Meeting Announcement
- Meeting Agenda (revised May 4)
- Meeting Summary
- Public Comments
Presentation Slides:
- Payment for Comprehensive Dementia Care: Five Key Recommendations
- Federal Agency Updates
- Therapies in Alzheimer’s Disease: The Approval Process and Implementing Scientific Discoveries and Advances into Patient Health
- Factors and Implementation for Traditional Medicare
- Prescribing Policy for Monoclonal Antibodies for Alzheimer’s Disease and Plans for Future Implementation: Challenges and Opportunities
- NAPA Research Subcommittee Historical Recommendations and Progress
- NAPA 2023: Have We Made Research Progress?
- Industry’s Role in Translating Research into Clinical Impact
- Programs Facilitating Integration of Disease-Modifying Therapies and Diagnostic Testing into Clinical Practice
Videos:
- "Welcome" through "Federal Updates"
- "Drug Approval and Coverage Decision Processes panel"
- "Progress, Challenges, and Opportunities… panel"
- "Discussion on Coordination of NAPA Goals" through "Adjourn"
January 30-31, 2023 — Advisory Council
During the meeting on January 30 and 31, the Advisory Council heard presentations on issues related to clinical practice and plans for advanced care planning. The second day presentations reviewed the impact of new drug approvals and focused on risk reduction and social determinants of health. The National Institute of Neurological Disorders and Stroke (NINDS) presented gaps and opportunities from the 2022 ADRD Summit, and other federal agencies provided updates.
General Material:
Presentation Slides:
- Federal Agency Updates
- Voice of a Person Living with Dementia
- Dementia Care Gaps and Recommendations for Improving Clinical Care and Quality of Life for People Living with Dementia and their Care Partners
- Suicide and Suicide Prevention Among Older Americans
- Alzheimer’s and Dementia Care ECHO Program for Primary Care Clinicians
- ADRD Summit 2022 and Research Milestones
- Clinical Care Considerations for Disease-modifying Therapies for Alzheimer’s Disease
- Social Determinants of Health and Risk Reduction: New Approach to Long-Standing Challenges
- From Data to Action in Alzheimer’s Disease Risk Reduction: Role of Social Determinants of Health
- Racism as a Social Determinant that Impacts Brain Health
- Place: Built and Natural Environment
Videos:
- "Day 1 Welcome" through "Federal Updates"
- "Clinical Care Panel" through "Day 1 Adjourn"
- "Day 2 Welcome" through "From Data to Action…"
- "Racism as a Social Determinant…" through "Day 2 Adjourn"
Comments and questions, or alerts to broken links, should be sent to napa@hhs.gov.